VIBATIV Drug Patent Profile
✉ Email this page to a colleague
When do Vibativ patents expire, and what generic alternatives are available?
Vibativ is a drug marketed by Cumberland and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-three patent family members in eighteen countries.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Vibativ
Vibativ was eligible for patent challenges on September 11, 2013.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 1, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VIBATIV
International Patents: | 33 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 16 |
Clinical Trials: | 13 |
Patent Applications: | 8 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIBATIV |
What excipients (inactive ingredients) are in VIBATIV? | VIBATIV excipients list |
DailyMed Link: | VIBATIV at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VIBATIV
Generic Entry Date for VIBATIV*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VIBATIV
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Joseph Kuti | Phase 4 |
Theravance Biopharma, US, Inc. | Phase 4 |
Joseph L. Kuti, PharmD | Phase 4 |
Pharmacology for VIBATIV
Drug Class | Lipoglycopeptide Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for VIBATIV
US Patents and Regulatory Information for VIBATIV
VIBATIV is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIBATIV is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VIBATIV
Hydrochloride salts of a glycopeptide phosphonate derivative
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIBATIV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIBATIV
See the table below for patents covering VIBATIV around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 522279 | Glycopeptide phosphonate derivatives | ⤷ Try a Trial |
Germany | 60122516 | ⤷ Try a Trial | |
Poland | 2495251 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 0198328 | ⤷ Try a Trial | |
Austria | 388960 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIBATIV
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1292612 | 91908 | Luxembourg | ⤷ Try a Trial | 91908, EXPIRES: 20260501 |
1292612 | 417 | Finland | ⤷ Try a Trial | |
1292612 | 122011100062 | Germany | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
1292612 | 36/2011 | Austria | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
1292612 | CA 2011 00033 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |